Anticoagulation Prophylaxis with Weight-Adjusted Enoxaparin Reduces Rates of Venous Thromboembolism in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase-Based Intensification Therapy

Conclusions: Weight-adjusted enoxaparin prophylaxis targeting 1 mg/kg/day reduced the incidence of symptomatic VTE in adult ALL patients receiving intensification chemotherapy with ASNase. This treatment is a viable VTE prevention option with no documented major bleeding.DisclosuresSchimmer: Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Otsuka Pharmaceuticals: Consultancy; Medivir AB: Research Funding; Jazz Pharmaceuticals: Consultancy. Schuh: Teva: Consultancy; Jazz: Consultancy; Pfizer: Consultancy; Amgen Inc.: Consultancy; Celgene: Consultancy; Novartis: Consultancy; Shire: Consultancy; Otsuka: Consultancy. Maze: Novartis: Consultancy, Honoraria. Yee: Celgene, Novartis, Otsuka: Membership on an entity's Board of Directors or advisory committees; Agensys, Astex, GSK, Onconova, Genentech/Roche: Research Funding. Gupta: Incyte: Research Funding; Novartis: Consultancy, Honoraria, Research Funding. Brandwein: Pfizer: Consultancy; Celgene: Consultancy; Lundbeck: Consultancy; Novartis: Consultancy; Boehringer Ingelheim: Consultancy, Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Sibai, H., Chen, R., Liu, X., Schimmer, A. D., Schuh, A., Law, A., McNamara, C. J., Maze, D., Yee, K. W. L., Minden, M. D., Chan, S. M., Gupta, V., Murphy, T., Falcone, U., Sakurai, N., Brandwein, J. M., Seki, J. Tags: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster III Source Type: research